高血清白介素-6水平与类风湿关节炎严重进展及Sarilumab治疗反应的事后分析
该事后分析基于MONARCH和MOBILITY两项III期研究,评估基线血清IL-6水平能否预测Sarilumab治疗反应。结果显示,基线IL-6高(≥3倍正常上限)的患者疾病活动度和关节破坏更重,且Sarilumab相较于阿达木单抗或甲氨蝶呤的临床改善幅度更大,提示IL-6可能作为预后标志物。
要点
- 基线IL-6≥3倍正常上限的RA患者疾病活动度和关节损伤更重。
- 高IL-6患者中Sarilumab相较阿达木单抗或MTX的临床改善幅度更大。
- IL-6和CRP均能预测治疗结局,安全性在各IL-6三分位组间相似。
核心结论
- IL-6可能是疾病进展和严重程度的预后标志物。
- 高IL-6水平患者可能更受益于Sarilumab而非阿达木单抗或MTX。
研究设计与样本
- MONARCH试验:Sarilumab 200 mg(n=148)或阿达木单抗40 mg(n=152)每2周,事后分析。
- MOBILITY试验:Sarilumab 150 mg(n=401)、200 mg(n=396)或安慰剂(n=397)每2周联合MTX,事后分析。
- 按IL-6三分位分组,用线性和逻辑回归比较疗效与患者报告结局。
主要发现
- MONARCH中,基线IL-6高(均≥3倍正常上限,n=100)者基线疾病活动度高于IL-6低者(n=100)。
- MONARCH中,高IL-6患者24周内Sarilumab相较阿达木单抗的临床改善幅度大于低IL-6患者。
- MOBILITY中,高IL-6(n=398)较低IL-6(n=397)基线疾病活动和关节损伤更高,更易关节进展。
- MOBILITY中,高IL-6患者52周安慰剂+MTX的临床改善少于Sarilumab 150 mg或200 mg+MTX。
- 基线IL-6和CRP水平均能预测结局,各IL-6三分位组安全性相似。
关键数值与推荐
- 高IL-6定义为所有值≥3倍正常上限(MONARCH中n=100)。
- MONARCH评估24周临床改善,MOBILITY评估52周临床改善。
临床怎么用
- 基线IL-6水平可能辅助识别疾病进展风险更高、更可能从Sarilumab获益的RA患者。
- 高IL-6患者使用Sarilumab相较阿达木单抗或MTX可能获得更大临床改善。
局限性
- 结果为事后分析,需前瞻性验证确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The development of biomarkers to guide treatment decisions is a major research focus in rheumatoid arthritis (RA). Patients with RA have elevated interleukin-6 (IL-6) levels; however, the utility of IL-6 as a predictor of treatment response is unclear. This study was undertaken to investigate, by post hoc analysis, whether baseline IL-6 levels are predictive of sarilumab treatment responses in 2 phase III studies. METHODS: Serum IL-6 concentrations were measured in patients with RA prior to receiving sarilumab 200 mg (n = 148) or adalimumab 40 mg (n = 152) every 2 weeks (in the MONARCH trial; ClinicalTrials.gov identifier: NCT02332590) or sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks plus methotrexate (MTX) (n = 401, n = 396, and n = 397, respectively) (in the MOBILITY trial; ClinicalTrials.gov identifier: NCT01061736). Efficacy and patient-reported outcomes were compared between and within groups according to IL-6 tertile using linear and logistic regression. RESULTS: In MONARCH, patients with high baseline IL-6 levels (all ≥3 times the upper limit of normal; n = 100) had higher disease activity at baseline than those with low IL-6 levels (n = 100). The magnitude of clinical improvement over 24 weeks with sarilumab versus adalimumab was greater in patients with high compared to those with low baseline IL-6 levels. In MOBILITY, compared to patients with low IL-6 levels (n = 397), patients with high IL-6 levels (n = 398) had higher disease activity and joint damage at baseline, were more likely to have joint progression, and had less clinical improvement over 52 weeks' treatment with placebo plus MTX compared to sarilumab 150 mg or 200 mg plus MTX. Baseline IL-6 and C-reactive protein levels were both predictive of outcomes. Safety profiles were similar between defined IL-6 tertiles. CONCLUSION: IL-6 may be a prognostic marker of disease progression and severity, and patients with high IL-6 levels may be likely to benefit from sarilumab compared to adalimumab or MTX. Prospective validation is warranted to confirm the results of these post hoc analyses.
引用
- Boyapati A, Schwartzman S, Msihid J, et al. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis Rheumatol. 2020. PMID: 32343882. doi:10.1002/art.41299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。